The U.S. Food and Drug Administration (FDA) is requesting public input on labeling and preventing cross-contact of gluten in packaged foods, following growing concerns from consumers and advocacy groups about the clarity and consistency of gluten disclosures.
Published in the Federal Register on January 22, 2026, the Request for Information (RFI) seeks data and real-world feedback to help the FDA evaluate whether current labeling practices adequately protect individuals with celiac disease and other gluten-related disorders.
Why This Matters
Under current U.S. regulations, wheat must be declared on food labels as a major allergen. However, other gluten-containing grains—such as barley and rye—are not subject to the same disclosure requirements. Additionally, foods like oats, which are naturally gluten-free, may be exposed to gluten through cross-contact during growing, harvesting, or processing.
For individuals who must strictly avoid gluten, even trace amounts can pose serious health risks. The FDA is evaluating whether existing labeling and manufacturing practices provide sufficient transparency and consumer protection.
What the FDA Is Evaluating
Through this RFI, the FDA is seeking information related to:
- The presence of non-wheat gluten sources in packaged foods
- Health impacts associated with gluten exposure from barley, rye, and cross-contact
- Manufacturing practices used to prevent gluten cross-contact
- Consumer understanding of current food labels and purchasing decisions
The feedback will help inform the FDA’s assessment of whether additional guidance or regulatory action may be necessary.
Comment Period
Deadline: March 23, 2026
Submit comments:
- Online: https://www.regulations.gov
- By mail: FDA Dockets Management Staff
Confidential submissions must follow FDA-specific instructions.
What Happens Next
This Request for Information does not introduce new requirements, but it may shape future FDA policy related to gluten labeling and cross-contact controls. Importers, manufacturers, and food distributors should monitor developments closely, as any regulatory changes could impact labeling, sourcing, and compliance obligations.
Speak to an Alba Expert for Support
If you have questions, please reach out, contact us.
